Research & Innovation

Open Clinical Trials:

Bladder Cancer (common type of bladder cancer is called Urothelial Carcinoma)

Study Title: A Phase II Open Label, Study of IMMU-132 in Mestastic Urothelia Cancer after Failure of Platium-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy
Primary Investigator: Dr. Alexandro Recio Boiles
 
Study Title: A Randomized Phase II of Atexolizumab with or without Bavacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer
Primary Investigator: Dr. Alexandro Recio Boiles
 
Study Title: A Randomized Phase II Study of Co-experssion Extrapolation (Coxen) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Primary Investigator: Dr. Jue Wang and Dr. Hani Babiker
 
Study Title: Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)
Primary Investigator: Hani Babiker
 
Study Title: An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY 1163877) in Combination with Atezolizumab as First-Line Treatment in Cisplatin-Ineligible Patients with FGFR-Positive Locally Advanced or Metastatic Urothelial Carcinoma
Primary Investigator: Dr. Hani Babiker
 
Kidney Cancer (also called Renal Cell Carcinoma)
Study Title: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Primary Investigator: Dr. Benjamin Lee
 
Study Title: Phase 1/1B, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Ageny and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
Primary Investigator: Dr. Alexandro Recio Boiles
 
Study Title: A Multicenter, open label, Phase 1B/2 Study to Evaluate Safety & Efficacy of Avelumab in combination with chemotherapy with or without other anti-cancer immunotherapies as 1st line treatment in patients with advanced malignancies​
Primary Investigator: Dr. Parminder Singh
 
Prostate Cancer
Study Title: A Multi-center, Randomized, Assessor-blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receivin Degarelix (GnRH Receptor Anatgonist) or Leuprolide (GnRH Receptor Agonist)
Primary Investigator: Dr.Benjamin Lee
 
Study Title: Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Mestatic Prostate Cancer
Primary Investigator: Dr. Juan Chipollini
 
Study Title: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Primary Investigator: Dr. Hani Babiker
 
Study Title: A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of a Vaccine-Based Regimine (VBIR) for Prostate Cancer
Primary Investigator: Dr. Hani Babiker
 
Study Title: Phase II-III trial of Adjuvant Radiotherapy and Androgen Deprivation Follwoing Radical Prostectomy with or without adjuvant Docetaxel 
Primary Investigator: Dr. Shona Dougherty
 
Study Title: A Phase 2, Randomized, Double-blind, Placebo Controlled Study of Abiraterone Aceate Plyus  Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
Primary Investigator: Dr. Alexandro Recio Boiles